Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study.

Kvorning T, Andersen M, Brixen K, Madsen K

American journal of physiology. Endocrinology and metabolism25 Jul 2006Cited by 118 (Europe PMC)

PMID16868226DOI10.1152/ajpendo.00143.2006PepBankPUB-16868226

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In young men, goserelin reduced testosterone from 22.6 +/- 5.5 to 2.0 +/- 0.5 at week 4 and 1.1 +/- 0.6 nmol/l at week 12; placebo levels remained constant.
In plain wordsIn young men, goserelin reduced testosterone compared with constant levels with placebo.
Peptide
Goserelin
Outcome
DecreaseTestosterone
Study
n = 22
Comparator
Placebo (saline)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 4 wk · subcutaneous · 12 wkAs given in this study (human).
Measurements
Endogenous testosterone
22.6 nmol/l
goserelin group, before
Endogenous testosterone
2 nmol/l
goserelin group, week 4
Endogenous testosterone
1.1 nmol/l
goserelin group, week 12
Source sentences
Summary
Endogenous testosterone decreased significantly (P < 0.01) in the goserelin group from 22.6 +/- 5.5 (mean +/- SD) nmol/l to 2.0 +/- 0.5 (week 4) and 1.1 +/- 0.6 nmol/l (week 12), whereas it remained constant in the placebo group.
3 context sentences(design, population, supporting numbers)
Summary · context
Twenty-two young men with minor experience with strength training participated in this randomized, placebo-controlled, double-blinded intervention study.
Summary · context
The subjects were randomized to treatment with the GnRH analog goserelin (3.6 mg) or placebo (saline) subcutaneously every 4 wk for 12 wk.
Summary · context
The strength training period of 8 wk, starting at week 4, included exercises for all major muscles [3-4 sets per exercise x 6-10 repetitions with corresponding 6- to 10-repetition maximum (RM) loads, 3/wk].
Report a problemFND-1686822601
02HumanRandomized controlled trialEfficacy outcome
In young men, strength did not change with goserelin, while placebo increased from 240.2 +/- 41.3 to 264.1 +/- 35.3 Nm (P = 0.05 between groups).
In plain wordsIn young men, knee extension strength remained unchanged with goserelin but increased with placebo.
Peptide
Goserelin
Outcome
DecreaseIsometric knee extension strength
Study
n = 22
Comparator
Placebo (saline)
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
3.6 mg every 4 wk · subcutaneous · 12 wkAs given in this study (human).
Measurements
Isometric knee extension strength
240.2 Nm
placebo group, before
Isometric knee extension strength
264.1 Nm
placebo group, after training
Source sentences
Summary
The goserelin group showed no changes in isometric knee extension strength after training, whereas the placebo group increased from 240.2 +/- 41.3 to 264.1 +/- 35.3 Nm (P < 0.05 within and P = 0.05 between groups).
3 context sentences(design, population, supporting numbers)
Summary · context
Twenty-two young men with minor experience with strength training participated in this randomized, placebo-controlled, double-blinded intervention study.
Summary · context
The subjects were randomized to treatment with the GnRH analog goserelin (3.6 mg) or placebo (saline) subcutaneously every 4 wk for 12 wk.
Summary · context
The strength training period of 8 wk, starting at week 4, included exercises for all major muscles [3-4 sets per exercise x 6-10 repetitions with corresponding 6- to 10-repetition maximum (RM) loads, 3/wk].
Report a problemFND-1686822602
03HumanRandomized controlled trialEfficacy outcome
In young men, leg lean mass increased 0.37 +/- 0.13 kg with goserelin versus 0.57 +/- 0.30 kg with placebo (P = 0.05 between groups).
In plain wordsIn young men, leg lean mass increased less with goserelin than placebo.
Peptide
Goserelin
Outcome
DecreaseLeg lean mass
Study
n = 22
Comparator
Placebo (saline)
Outcome group
Body composition · Musculoskeletal
Studied dose
3.6 mg every 4 wk · subcutaneous · 12 wkAs given in this study (human).
Measurements
Leg lean mass change
0.37 kg
goserelin group
Leg lean mass change
0.57 kg
placebo group
Source sentences
Summary
Lean mass of the legs increased 0.37 +/- 0.13 and 0.57 +/- 0.30 kg in the goserelin and placebo groups, respectively (P < 0.05 within and P = 0.05 between groups).
3 context sentences(design, population, supporting numbers)
Summary · context
Twenty-two young men with minor experience with strength training participated in this randomized, placebo-controlled, double-blinded intervention study.
Summary · context
The subjects were randomized to treatment with the GnRH analog goserelin (3.6 mg) or placebo (saline) subcutaneously every 4 wk for 12 wk.
Summary · context
The strength training period of 8 wk, starting at week 4, included exercises for all major muscles [3-4 sets per exercise x 6-10 repetitions with corresponding 6- to 10-repetition maximum (RM) loads, 3/wk].
Report a problemFND-1686822603
04HumanRandomized controlled trialEfficacy outcome
In young men, fat mass increased 1.4 +/- 1.0 kg with goserelin and decreased 0.6 +/- 1.2 kg with placebo (P < 0.05).
In plain wordsIn young men, fat mass increased with goserelin but decreased with placebo.
Peptide
Goserelin
Outcome
IncreaseBody fat mass
Study
n = 22
Comparator
Placebo (saline)
Outcome group
Body composition · Metabolic and weight
Studied dose
3.6 mg every 4 wk · subcutaneous · 12 wkAs given in this study (human).
Measurements
Body fat mass change
1.4 kg
goserelin group
Body fat mass change
−0.6 kg
placebo group
Source sentences
Summary
Body fat mass increased 1.4 +/- 1.0 kg and decreased 0.6 +/- 1.2 kg in the goserelin and placebo groups, respectively (P < 0.05 within and between groups).
3 context sentences(design, population, supporting numbers)
Summary · context
Twenty-two young men with minor experience with strength training participated in this randomized, placebo-controlled, double-blinded intervention study.
Summary · context
The subjects were randomized to treatment with the GnRH analog goserelin (3.6 mg) or placebo (saline) subcutaneously every 4 wk for 12 wk.
Summary · context
The strength training period of 8 wk, starting at week 4, included exercises for all major muscles [3-4 sets per exercise x 6-10 repetitions with corresponding 6- to 10-repetition maximum (RM) loads, 3/wk].
Report a problemFND-1686822604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT03054168

Systemic Hormones and Muscle Protein Synthesis

University of Nottinghamn = 3415 Dec 2016 to est. 15 Feb 2019

Sarcopenia · Muscle Hypotrophy · Muscle Atrophy

Trial page ClinicalTrials.govUpdated 26 Feb 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.